Bulk RNA-seq analysis of primary CML CD34+ cells (n=3) treated with idasanutlin alone or in combination with nilotinib in vitro
Ontology highlight
ABSTRACT: Bulk RNA-seq was performed on primary human CML CD34+ cells to understand the molecular consequences of treatment with the MDM2 inhibitor idasanutlin alone and in combination with the tyrosine kinase inhibitor nilotinib for 24 hrs and 72 hrs.
ORGANISM(S): Homo sapiens
PROVIDER: GSE218183 | GEO | 2023/12/19
REPOSITORIES: GEO
ACCESS DATA